Metastatic renal cell carcinoma

You have access
Morphomics Can Predict Oncological Features and Survival of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy
I-HUNG SHAO, YING-HSU CHANG, TING-WEN SHENG, CHIN-CHIEH TAN, LI-JEN WANG, CHENG-KENG CHUANG, CHUN-TE WU and SEE-TONG PANG

Anticancer Research October 2021, 41 (10) 5203-5211; DOI: https://doi.org/10.21873/anticanres.15339
You have access
Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer
SHOTARO YASUOKA, TAKESHI YUASA, RYO FUJIWARA, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, YUKIHIRO KONDO and JUNJI YONESE

Anticancer Research November 2020, 40 (11) 6493-6497; DOI: https://doi.org/10.21873/anticanres.14671
You have access
Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma
KIYOSHI TAKAHARA, RYOSUKE ANDO, KENT KANAO, TOSHIKI ITO, HIDEAKI MIYAKE, MAKOTO SUMITOMO, TAKAHIRO YASUI and RYOICHI SHIROKI

Anticancer Research August 2020, 40 (8) 4395-4400; DOI: https://doi.org/10.21873/anticanres.14443
You have access
Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report
LUCAS ZARLING, HAMID EMAMEKHOO, GAURI BHUTANI, TIMOTHY ZIEMLEWICZ, KRISTINA A. MATKOWSKYJ and CHRISTOS E. KYRIAKOPOULOS

Anticancer Research March 2020, 40 (3) 1527-1534; DOI: https://doi.org/10.21873/anticanres.14098
You have access
The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma
JIAN-RI LI, YEN-CHUAN OU, CHENG-KUANG YANG, SHIAN-SHIANG WANG, CHUAN-SU CHEN, HAO-CHUNG HO, CHEN-LI CHENG, CHI-REI YANG, CHENG-CHE CHEN, SHU-CHI WANG, CHIA-YEN LIN, SHENG-CHUN HUNG, CHIANN-YI HSU and KUN-YUAN CHIU

Anticancer Research September 2018, 38 (9) 5339-5345; DOI: https://doi.org/10.21873/anticanres.12861
You have access
Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years
HIDEAKI MIYAKE, RYOTA AKI, YUTO MATSUSHITA, KEITA TAMURA, DAISUKE MOTOYAMA, TOSHIKI ITO, TAKAYUKI SUGIYAMA and ATSUSHI OTSUKA

Anticancer Research June 2018, 38 (6) 3593-3599; DOI: https://doi.org/10.21873/anticanres.12633
You have access
Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors
PAWEL CHROM, RAFAL STEC, LUBOMIR BODNAR and CEZARY SZCZYLIK

Anticancer Research January 2018, 38 (1) 359-365;
You have access
Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma
HIDEAKI MIYAKE, SATOSHI IMAI, KEITA TAMURA, TAKAYUKI SUGIYAMA, HIROSHI FURUSE, SEIICHIRO OZONO and MASATO FUJISAWA

Anticancer Research March 2017, 37 (3) 1523-1528;
You have access
Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma
YUTA TAKEZAWA, KOUJI IZUMI, YUSUKE SHIMURA, MAOLAKE AERKEN, ARIUNBOLD NATSAGDORJI, MASASHI IIJIMA, KAZUYOSHI SHIGEHARA, TAKAHIRO NOHARA, KAZUTAKA NARIMOTO, YOSHIFUMI KADONO, YASUHIDE KITAGAWA, HIROYUKI KONAKA and ATSUSHI MIZOKAMI

Anticancer Research September 2016, 36 (9) 4961-4964;
You have access
No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma
AKIRA MIYAZAKI, HIDEAKI MIYAKE, KEN-ICHI HARADA and MASATO FUJISAWA

Anticancer Research May 2015, 35 (5) 3067-3073;

Main menu

User menu

Search

Metastatic renal cell carcinoma

Pages